Preclinical review finds CBD effects on nitric oxide vary by enzyme
Isoform-Selective and Context-Dependent Modulation of Nitric Oxide Synthase by Cannabidiol: A Mechanistic Review of Preclinical Evidence in Neurological and Neuropathic Disorders.
AI Summary
This narrative review asks how cannabidiol (CBD) affects the nitric oxide synthase (NOS) enzymes nNOS, iNOS, and eNOS. It draws mainly on preclinical evidence from cell and animal models, rather than reporting a new clinical study. Its strongest finding is that CBD can suppress excessive iNOS expression and nitric oxide production in neuroinflammatory conditions.
Effects on nNOS are mixed and depend on the biological context: CBD may reduce harmful excitotoxicity in some models, yet nNOS-derived signaling contributes to CBD-related pain relief in certain neuropathic pain models. Evidence for eNOS effects in the brain is preliminary. This abstract-based summary reflects a narrative review; the evidence described cannot establish clinical benefit, and the review identifies a need for clinical trials using relevant biomarkers.
π‘ Key Findings
π
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
Randomized trial finds CBD did not reduce severe behavioral problems
Preclinical evidence finds no stable CBD dose-response for fear
Post hoc TSC analysis links caregiver-perceived improvement to seizureβ¦
Explore More Research
Stay informed about the latest cannabis science.